• Endocyte Inc., of West Lafayette, Ind., said the World Health Organization and the United States Adopted Names Council approved the nonproprietary name "vintafolide" for ovarian cancer drug EC145 and the nonproprietary name "etarfolatide" for companion imaging agent EC20.